SCHEMBL4514855

SCHEMBL4514855

O=C1N(Cc2c(Cl)cccc2Cl)CCN1N1CCOCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 4/20 0.55
KDM4E B2RXH2 2/20 0.44
NPSR1 Q6W5P4 2/20 0.39
HTT P42858 1/20 0.39
DRD3 P35462 2/20 0.39
KCNH2 Q12809 2/20 0.39
DRD2 P14416 1/20 0.39
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
PIK3CA P42336 1/20 0.38
PIK3CB P42338 1/20 0.38
P2RX7 Q99572 3/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4515061 0.86 NPSR1 (0.40) CYP2A13KDM4ENPSR1HTTDRD3
SCHEMBL4513935 0.80 CYP2D6 (0.53) CYP2A13KDM4ENPSR1HTTDRD3
SCHEMBL4501138 0.73 CYP2D6 (0.59) KDM4ENPSR1DRD3KCNH2DRD2
SCHEMBL4503707 0.73 P2RX7 (0.45) CYP2A13KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL4524082 0.72 POLB (0.51) NPSR1HTTDRD3KCNH2DRD2
SCHEMBL4097834 0.72 CYP2A13 (1.00) CYP2A13KDM4EHTTALDH1A1MEN1
SCHEMBL4510323 0.72 P2RX7 (0.51) CYP2A13NPSR1HTTDRD3KCNH2
SCHEMBL4518008 0.70 CYP2A13 (0.46) CYP2A13KDM4ENPSR1ALDH1A1PIK3CA
SCHEMBL4503325 0.70 CYP2D6 (0.74) KDM4ENPSR1ALDH1A1CYP1A2CYP3A4
SCHEMBL4500988 0.70 KCNH2 (0.48) CYP2A13KDM4ENPSR1HTTDRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 CYP2A13 109/4885KDM4E 2703/4885NPSR1 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.